https://novaprd-lb.newcastle.edu.au/vital/access/manager/Index en-au 5 The MSReactor computerized cognitive battery correlates with the processing speed test in relapsing-remitting multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:39575 Wed 27 Jul 2022 14:43:55 AEST ]]> Defining reliable disability outcomes in multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:22648 Wed 22 May 2019 14:50:34 AEST ]]> Patient-determined disease steps is not interchangeable with the Expanded Disease Status Scale in mild to moderate multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:54397 Wed 21 Feb 2024 15:48:45 AEDT ]]> Predictors of disability worsening in clinically isolated syndrome https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:28397 Wed 11 Apr 2018 15:14:13 AEST ]]> Comparative efficacy of switching to natalizumab in active multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:25641 Wed 11 Apr 2018 15:12:45 AEST ]]> Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:28923 Wed 11 Apr 2018 10:33:05 AEST ]]> The Australian Multiple Sclerosis (MS) Immunotherapy Study: a prospective, multicentre study of drug utilisation using the MSBase platform https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:13692 Wed 11 Apr 2018 09:50:56 AEST ]]> Prediction of multiple sclerosis outcomes when switching to ocrelizumab https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:46515 Thu 24 Nov 2022 15:50:23 AEDT ]]> Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:36736 Thu 02 Jul 2020 16:31:45 AEST ]]> Fingolimod after natalizumab and the risk of short-term relapse https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:20798 Sat 24 Mar 2018 08:05:59 AEDT ]]> Predictors and dynamics of postpartum relapses in women with multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:17471 Sat 24 Mar 2018 08:04:07 AEDT ]]> Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:19533 95% of the identified indication bias. Slightly lower relapse incidence was found among patients treated with glatiramer acetate or subcutaneous interferon β-1a relative to intramuscular interferon β-1a and interferon β-1b (p≤0.001). No differences in 12-month confirmed progression of disability were observed. Conclusion: Small but statistically significant differences in relapse outcomes exist among the injectable immunomodulators. MSBase is sufficiently powered to identify these differences and reflects practice in tertiary MS centres. While the present study controlled indication, selection and attrition bias, centre-dependent variance in data quality was likely.]]> Sat 24 Mar 2018 08:02:06 AEDT ]]> Seasonal variation of relapse rate in multiple sclerosis is latitude dependent https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:19821 Sat 24 Mar 2018 07:56:56 AEDT ]]> Risk of relapse phenotype recurrence in multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:20329 Sat 24 Mar 2018 07:55:11 AEDT ]]> The CYP27B1 variant associated with an increased risk of autoimmune disease is underexpressed in tolerizing dendritic cells https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:19680 Sat 24 Mar 2018 07:53:39 AEDT ]]> Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:30101 Sat 24 Mar 2018 07:37:59 AEDT ]]> Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:29942 -23). A reciprocal relationship was seen for ambient ultraviolet radiation (UVR), with a significantly increasing AAO for patients with MS per each quartile increment of ambient UVR (p=1.56×10-17). We found that the AAO of female patients was ~5 months earlier than male patients (p=0.002). AAO of progressive-onset patients with MS were ~9 years later than relapsing-onset patients (p=1.40×10-265). Conclusions: An earlier AAO in higher latitude regions was found in this worldwide European-descent cohort and correlated inversely with variation in latitudinal UVR. These results suggest that environmental factors which act at the population level may significantly influence disease severity characteristics in genetically susceptible populations.]]> Sat 24 Mar 2018 07:31:01 AEDT ]]> Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: a contemporary cohort study https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:41847 p = 0.010); but no differences in spontaneous abortions, term or preterm births. Conclusions: We report low pregnancy incidence rates, with increasing number of pregnancies conceived on DMT over the past 12-years. The median duration of DMT exposure in pregnancy was relatively short at one month.]]> Mon 15 Aug 2022 10:27:59 AEST ]]> Association between cognitive trajectories and disability progression in patients with relapsing-remitting multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:46218 Mon 14 Nov 2022 12:12:01 AEDT ]]> Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:41309 Mon 01 Aug 2022 12:30:36 AEST ]]> Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:53317 Fri 19 Jan 2024 14:25:45 AEDT ]]>